Technetium-99m (⁹⁹mTc)-labelled sulesomab in the management of malignant external otitis: is there any role?

Eur Arch Otorhinolaryngol. 2015 Jun;272(6):1377-82. doi: 10.1007/s00405-014-2938-1. Epub 2014 Feb 18.

Abstract

We report two cases of malignant external otitis (MEO) evaluated with Technetium-99m((99m)Tc)-labelled sulesomab. Two patients affected by MEO are presented, together with a literature review. Both patients were studied with clinical examination, ear discharge culture, radiological imaging, blood exams, (99m)Tc Sulesomab, and treated with antibiotic therapy. (99m)Tc-Sulesomab would appear to be an useful tool for diagnosis and follow-up of MEO, highlighting the site and extension of the inflammatory process, and evaluating course and treatment efficacy. (99m)Tc-Sulesomab shows promise as a rapid, effective and safe imaging agent for treatment response evaluation and follow-up of patients with MEO. Further studies are warranted to validate the inclusion of (99m)Tc-Sulesomab scan in the imaging follow-up of patients with MEO.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Anti-Bacterial Agents / administration & dosage*
  • Antibodies, Monoclonal, Murine-Derived / pharmacology*
  • Coinfection* / diagnosis
  • Coinfection* / drug therapy
  • Coinfection* / microbiology
  • Diabetes Complications / microbiology*
  • Diagnosis, Differential
  • Disease Management
  • Drug Monitoring / methods
  • Humans
  • Male
  • Otitis Externa* / diagnosis
  • Otitis Externa* / drug therapy
  • Otitis Externa* / microbiology
  • Proteus mirabilis / isolation & purification
  • Pseudomonas aeruginosa / isolation & purification
  • Radionuclide Imaging / methods*
  • Radiopharmaceuticals / pharmacology
  • Staphylococcus epidermidis / isolation & purification
  • Treatment Outcome

Substances

  • Anti-Bacterial Agents
  • Antibodies, Monoclonal, Murine-Derived
  • Radiopharmaceuticals
  • Sulesomab